Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Four biosimilars for Stelara have launched in the United States this year following legal settlements with the reference ...

Proficio Capital Partners LLC massively increased its stake in Amgen, acquiring 470,808 shares in Q4. This move significantly ...

Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...

Amgen and AstraZeneca's Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial.

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...

Gulf International Bank UK Ltd reduced its stake in Amgen by 2.5%, selling 1,041 shares in Q4. Several other institutional ...

(Alliance News) - An asthma drug has shown positive results when used to treat nasal polyps, researchers have said. Tezepelumab was first approved for treating asthma in 2021, but new research led by ...

Amgen Inc. (NASDAQ:AMGN – Get Free Report) was the target of some unusual options trading activity on Friday. Stock traders ...

Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a ...

We recently compiled a list of the 18 AI News and Ratings Making Waves on Wall Street. In this article, we are going to take ...